Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434539 | 0.88 | AGTR1 (0.51) | MAPTPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3331994 | 0.76 | HTR6 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8188816 | 0.75 | AGTR1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17521582 | 0.75 | PCSK9 (0.62) | MAPTPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14595058 | 0.74 | L3MBTL1 (0.63) | HTR6AGTR1KDM4E | |
| SCHEMBL1778448 | 0.73 | MAPT (0.46) | MAPTHTR6GAAPDE4BMEN1 | |
| SCHEMBL1779448 | 0.72 | MAPT (0.48) | MAPTHTR6GAAPDE4BMEN1 | |
| SCHEMBL1779946 | 0.71 | MAPT (0.46) | MAPTHTR6GAAPDE4BMEN1 | |
| SCHEMBL4040857 | 0.71 | MAPT (0.57) | MAPTGAAMEN1KMT2APOLB | |
| SCHEMBL1777566 | 0.71 | MAPT (0.45) | MAPTPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2113012-B1 | METHOD FOR PRODUCING THE PIGMENT RED 149 | BASF SE (DE) | 2012-08-29 | — | — | EP | claimed |
| EP-2113012-A2 | METHOD FOR PRODUCING THE PIGMENT RED 149 | BASF SE (DE) | 2009-11-04 | — | — | EP | claimed |
| WO-2008101895-A2 | METHOD FOR PRODUCING THE PIGMENT RED 149 | BASF SE (DE) | 2008-08-28 | — | — | WO | claimed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| EP-2081892-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | Queen's University at Kingston (CA) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008058402-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | MAPT 2/4885PSEN1 6/4885PSEN2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.